Description: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia.
Home Page: scholarrock.com
SRRK Technical Analysis
301 Binney Street
Cambridge,
MA
02142
United States
Phone:
857 259 3860
Officers
| Name | Title |
|---|---|
| Mr. Edward H. Myles M.B.A., MBA | CFO, COO & Treasurer |
| Dr. Jay T. Backstrom M.D., M.P.H. | Pres, CEO & Director |
| Ms. Catherine Hu | VP of Investor Relations & Corp. Communications |
| Ms. Junlin Ho J.D. | Gen. Counsel & Corp. Sec. |
| Ms. Caryn Parlavecchio | Chief HR Officer |
| Ms. Lisa Amaya Price | Sr. VP of HR |
| Dr. George G. Nomikos M.D., Ph.D. | Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area |
| Ms. Erin Moore | Sr. VP of Fin. |
| Mr. Ryan Iarrobino | Sr. VP of Clinical Devel. & Operations |
| Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5203 |
| Price-to-Sales TTM: | 11.3337 |
| IPO Date: | 2018-05-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 145 |